QIAGEN N.V.

QIAGEN announces new milestones for its QuantiFERON tuberculosis test

(PRESS RELEASE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN N.V. (NYSE: QGEN; Frankfurt…

2 years ago

QIAGEN N.V. forms joint venture with Maccura Biotechnology Co., Ltd., a leading in vitro diagnostics (IVD) company in China

Partnership with a leading Chinese IVD company with goal to accelerate penetration of the world’s first complete Sample to Insight…

7 years ago

QIAGEN N.V. and Hamilton Robotics to serve the growing need for DNA fingerprinting of samples for human identity databases

Partnering with Hamilton Robotics to deliver automated workflows for DNA fingerprinting  Hilden, Germany, and Germantown, Maryland, 13-Oct-2016 — /EuropaWire/ — QIAGEN…

8 years ago

QIAGEN N.V. to submit conditional voluntary takeover offer to purchase all shares in Exiqon

Transaction will expand leadership position in RNA technologies Venlo, The Netherlands, 01-Apr-2016 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt…

8 years ago

QIAGEN N.V. starts commercialization activities for its GeneReader NGS System

First truly end-to-end solution brings next-generation sequencing within reach for any lab Austin, Texas, and Hilden, Germany, 6-11-2015 — /EuropaWire/…

8 years ago

QIAGEN N.V. to increase global access to advanced cervical cancer screening technologies for women most in need

Global launch of CE marked careHPV and new CE marked self-collection claim for HPV sampling device help to provide HPV…

9 years ago

QIAGEN N.V. announces new capabilities for its Ingenuity® Variant Analysis™ and CLC Cancer Research Workbench solution

Translational research in cancer and other diseases will benefit from new capabilities being presented at the American Society of Human…

10 years ago